TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04557761

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: microMend®
Description: microMend® is a novel wound closure device that consists of arrays of tiny staples, known as Microstaples, which are attached to a backing material that is the size and shape of a butterfly closure. The Microstaples enable secure attachment of the device to the skin, allowing for the safe closure of wounds associated with surgery and traumatic injuries, such as lacerations. microMend is listed with the FDA and is available for sale in the United States.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Closure with Sutures
Description: The Subject's laceration will be closed with sutures per regular institutional policies and procedures.
Study: NCT00715416

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nitinol Stent Placement
Description: Balloon angioplasty compared to primary stent implantation for long segment superficial femoral artery lesions
Study: NCT00902395

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: Oral midazolam 1.0 mg/kg (maximum 20 mg)

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Protective stabilization
Description: Children will receive a protective stabilization (physical restrain) with sheet fixed with tapes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam, ketamine
Description: Combined oral midazolam (0.5 mg/kg) and ketamine (3 mg/kg) (MK)
Study: NCT04061928

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1
Description: 2 times PD-1 (240mg) combined with preoperative chemoradiotherapy，then another 2 times PD-1 before operation. 4 times PD-1 combined with postoperative chemotherapy.
Study: NCT01766193

Intervention type: PROCEDURE
Intervention: vaginal delivery

Intervention type: PROCEDURE
Intervention: forceps extraction
Description: vaginal delivery by forceps extraction

Intervention type: PROCEDURE
Intervention: vacuum extraction
Description: vaginal delivery by vacuum extraction

Intervention type: PROCEDURE
Intervention: cesarean section
Study: NCT04807491

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuromuscular Re-Education
Description: After the baseline assessment, the participant in the control will receive Neuromuscular Re-Education. The duration of session will be 45 minutes.Neuromuscular Re-Education: For initiation (acute phase): Active-assisted exercise,Massage and stretch for affected side.For Facilitation ,Active-assisted exercise.For Movement control:Massage and stretching for facial retraction,Assisted and active exercises on involved side.~For Relaxation,Thermotherapy,Relaxation exercises,Alternating rhythmic movements.~Conventional therapy exercises
Study: NCT00181298

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Memantine
Description: Dispensing initially 5 mg. Dose Increased by 5 mg weekly to 20 mg/d final dose by week 4.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dispensing initially 5 mg. Dose Increased by 5 mg weekly to 20 mg/d final dose by week 4
Study: NCT03648450

Intervention type: OTHER
Intervention: Propeller EMD
Description: Propeller electronic monitoring device is a sensor that fits on top of inhalers and uses Bluetooth connection to cell phones to remind patients to take their medication.
Study: NCT03638011

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exparel
Description: Bilateral TAP Blocks with combination of regular Bupivacaine and EXPAREL
Study: NCT00117962

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: 400 mg/sq m IV over 120 min: Day 1; Week 1 250 mg/sq m IV over 60 min weekly for 6 more weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: AUC = 5 q 21 days for 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: AUC = 5 q 21 days for 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed disodium
Description: 500 mg/sq m IV q 21 days during chemoradiation and consolidation chemotherapy phases

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed disodium
Description: 500 mg/sq m IV q 21 days during chemoradiation and consolidation chemotherapy phases

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Thoracic radiotherapy: 70 Gy for 7 weeks beginning on Day 1.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Thoracic radiotherapy: 70 Gy for 7 weeks beginning on Day 1.
Study: NCT03458806

Intervention type: DIAGNOSTIC_TEST
Intervention: AS Algorithm 1
Description: Machine learning algorithm, generated from ECG and PCG recordings, distinguishing moderate-to-severe or greater aortic stenosis from controls having structurally normal hearts with no greater than mild valvular heart disease at any location.

Intervention type: DIAGNOSTIC_TEST
Intervention: AS Algorithm 1
Description: Machine learning algorithm, generated from ECG and PCG recordings, distinguishing moderate-to-severe or greater aortic stenosis from controls having structurally normal hearts with no greater than mild valvular heart disease at any location.

Intervention type: DIAGNOSTIC_TEST
Intervention: AS Algorithm 2
Description: Machine learning algorithm, generated from ECG and PCG recordings, distinguishing moderate-to-severe or greater aortic stenosis from controls having any findings other than moderate-to-severe or greater aortic stenosis.

Intervention type: DIAGNOSTIC_TEST
Intervention: AS Algorithm 2
Description: Machine learning algorithm, generated from ECG and PCG recordings, distinguishing moderate-to-severe or greater aortic stenosis from controls having any findings other than moderate-to-severe or greater aortic stenosis.

Intervention type: DIAGNOSTIC_TEST
Intervention: MR Algorithm 1
Description: Machine learning algorithm, generated from ECG and PCG recordings, distinguishing moderate-to-severe or greater mitral regurgitation from controls having structurally normal hearts with no greater than mild valvular heart disease at any location.

Intervention type: DIAGNOSTIC_TEST
Intervention: MR Algorithm 1
Description: Machine learning algorithm, generated from ECG and PCG recordings, distinguishing moderate-to-severe or greater mitral regurgitation from controls having structurally normal hearts with no greater than mild valvular heart disease at any location.

Intervention type: DIAGNOSTIC_TEST
Intervention: MR Algorithm 2
Description: Machine learning algorithm, generated from ECG and PCG recordings, distinguishing moderate-to-severe or greater mitral regurgitation from controls having any findings other than moderate-to-severe or greater mitral regurgitation.

Intervention type: DIAGNOSTIC_TEST
Intervention: MR Algorithm 2
Description: Machine learning algorithm, generated from ECG and PCG recordings, distinguishing moderate-to-severe or greater mitral regurgitation from controls having any findings other than moderate-to-severe or greater mitral regurgitation.
Study: NCT03265392

Intervention type: OTHER
Group type: OTHER
Intervention: Bread
Description: Serving of wheat bread providing 50 g of carbohydrates

Intervention type: OTHER
Group type: OTHER
Intervention: Bread
Description: Serving of wheat bread providing 50 g of carbohydrates
Study: NCT03194425

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Pelvic floor EMG
Description: Define pelvic floor EMG template measured by probe

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Pelvic floor EMG
Description: Define pelvic floor EMG template measured by probe
Study: NCT03846947

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MR Fingerprinting
Description: The MR fingerprinting technique requires less than 15 minutes total and will be added before and after the standard MRI sequence.
Study: NCT00755001

Intervention type: DEVICE
Intervention: BiHapro hip stem with PPS Ti+Plasma HA
Description: BiHapro hip stem with PPS Ti+Plasma HA

Intervention type: DEVICE
Intervention: BiHapro hip stem with PPS Ti+BoneMaster HA
Description: BiHapro hip stem with PPS Ti+BoneMaster HA
Study: NCT01498991

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AMES Treatment
Description: The AMES device rotates the ankle over a range of 30 degrees while vibrators stimulate the tendons attached to muscles that move the leg. Each participant will receive treatment of both lower extremities. Treatment of the 2 legs will be scheduled to run in the same session. The subject's task is to assist the motion of the device. The AMES treatment device couples assisted movement and tendon vibration (enhanced sensation) in 30 treatments which will each run approximately 40 minutes (20 minutes on the right leg and 20 minutes on the left leg).
Study: NCT02123329

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pharmacist delivered smoking cessation program
Description: The first session will be time-intensive taking around 30 minutes. In this session, the study pharmacist will facilitate the participant's preparation to quit. The participant will select a quit date within the next 2-4 weeks. The pharmacist will discuss with the participant the benefits of smoking cessation and will provide him or her with tailored behavioral and lifestyle strategies.~To prevent nicotine withdrawal symptoms, the participant will be offered nicotine replacement therapy (NRT) The first follow-up session will be scheduled after 1 week of the participant's quit day and will take around 20 minutes. In this session, the pharmacist will determine the participant's smoking status and assess the NRT tolerability.~• If the participant fails to quit smoking, the pharmacist will carefully review the participant's experience during the attempt to quit and will work through the identified problems

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control arm (i.e: regular care)
Description: Participants in the control group will receive 5-10 minutes of unstructured brief smoking cessation advice by the pharmacist. In addition they will be provided with educational materials about smoking cessation and will be offered nicotine replacement therapy (NRT).
Study: NCT01086683

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychosocial rehabilitation course
Description: Groups of 20 cancer survivors participated in a 6-day multi-focused, psychosocial intervention at the Dallund rehabilitation centre. The overall aim was to strengthen each individual's physical, psychological and social functioning. Sharing experiences with other cancer patients and experiencing peer-support was a central issue. The retreat combined lectures, discussions and patient group work on themes such as the treatment of cancer, psychological reactions, spirituality, sexuality and lifestyle. Participants were involved in physical activities, and the daily menu represented a healthy diet. The course was conducted by a multi-disciplinary team. Each participant produced a personal, specific 'action plan', which was intended to serve as a 'booster' after returning to daily life.
Study: NCT01584024

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Resin infiltration
Description: Baseline treatment of one caries lesion with resin infiltration therapy, in addition to preventative measures and behavioral modification.~ICON product: FDA-510(k): K100062

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham treatment
Description: Baseline treatment of one caries lesion with sham treatment, in addition to preventative measures and behavioral modification.
Study: NCT02649933

Intervention type: DEVICE
Intervention: Watch PAT 200
Description: screening of OSA with Watch PAT 200
Study: NCT00753636

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dynacirc CR (Isradipine)
Description: Dynacirc CR is given by the recommended schedule for titration. Subjects start on a 5mg dose and are increased in increments of 5mg every 2 weeks provided that the subjects do not have significant adverse events or symptomatic orthostatic hypotension.
Study: NCT01568944

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Antibiotic and Oral Rinse
Description: PO Amoxicillin in 500 mg / Metronidazole 250 mg of each TID for 8 days plus 2 ounces of 0.12% chlorhexidine mouthrinse used BID

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard Treatment
Description: Full mouth scaling and root planing using hand instrumentation (curettes) and ultrasonic scalers
Study: NCT05230927

Intervention type: OTHER
Intervention: Multidisciplinary Rehabilitation
Description: All patients admitted to an inpatient rehabilitation program will undergo medical history collection, physical, clinical, and functional examination, exercise testing, educational sessions, exercise training (cycle ergometer/treadmill, arm ergometer, breathing, and strength exercises where indicated, calisthenics exercises), psychological counseling, and metabolic evaluation with a personalized diet when needed.
Study: NCT01568944

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Standard Treatment
Description: Full mouth scaling and root planing using hand instrumentation (curettes) and ultrasonic scalers
Study: NCT02650310

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thermostable device
Description: Investigators place the catheter with the loaded embryos into a plastic device at 37ºC in order to maintain the temperature
Study: NCT04453150

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard hypocaloric die
Description: Standard hypocaloric diet

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intermittent fasting 16/8 (early fasting)
Description: Intermittent fasting 16/8 (early fasting)
Study: NCT05392660

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: assumed upright position during first stage of labor
Description: The study group assumed one of upright positions during first stage of labor, defined as walking , sitting, standing, kneeling \& squatting positions )
Study: NCT04453150

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intermittent fasting 16/8 (late fasting)
Description: Intermittent fasting 16/8 (late fasting)
Study: NCT02960906

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: For Arms 2C and 3C (TKI pazopanib or sunitinib):~Sunitinib 50 mg orally QD until disease progression, unacceptable toxicity or other reasons specified in the protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: For Arms 2C and 3C (TKI pazopanib or sunitinib):~Sunitinib 50 mg orally QD until disease progression, unacceptable toxicity or other reasons specified in the protocol
Study: NCT02612675

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ONS

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ONS
Study: NCT01719276

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Graded Activity
Description: The graded activity program to increase activity tolerance by performing individualized and submaximal exercises.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Graded Activity
Description: The graded activity program to increase activity tolerance by performing individualized and submaximal exercises.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Supervised Exercises
Description: The group will perform stretching exercises (gluteus maximus, hamstrings, triceps surae, lumbar paraspinal), strengthening muscles (rectus abdominus, obliques and lower rectus abdominis internal and external) and motor control exercises (muscle transversus abdominis and lumbar multifidus.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Supervised Exercises
Description: The group will perform stretching exercises (gluteus maximus, hamstrings, triceps surae, lumbar paraspinal), strengthening muscles (rectus abdominus, obliques and lower rectus abdominis internal and external) and motor control exercises (muscle transversus abdominis and lumbar multifidus.
Study: NCT03421561

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stellarex 0.035 OTW Drug-coated Angioplasty Balloon
Description: The Stellarex 0.035 OTW Drug-coated Angioplasty Balloon is indicated for percutaneous transluminal angioplasty (PTA), after appropriate vessel preparation, of de novo or restenotic lesions up to 180 mm in length in native superficial femoral or popliteal arteries with reference vessel diameters of 4-6 mm.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: EverCross™ 0.035 PTA Balloon Catheter
Description: The control device is a commercially available PTA balloon catheter (EverCross™ 0.035 PTA Balloon Catheter, Medtronic, Plymouth, MN 55441, USA).
Study: NCT00250718

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Vincristine should be administered intravenously through a freely-running IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VP-16
Description: The VP-16 is optional for the first cycle if the patient has delays in obtaining the drug.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: The total amount of rituximab needed for a patient's entire infusions (one course) will be determined at study entry. A single dose of 375 mg/m2 will be based upon the patient's actual body surface area calculated during the baseline evaluation. The dose level of rituximab will not be adjusted.~Patients will only receive rituximab if their tumors are CD20 positive CLL or NHL.~Rituximab will only be administered to patients if they have previously had less than 8 doses. If a patient is treated with rituxan they should have at least 4 doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone will be administered at 200mg q 14 days. Dexamethasone should be administered over a 1 hour infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levofloxacin
Description: Levofloxacin will be administered at 500 mg PO qd.
Study: NCT03015701

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifepristone
Description: a 19 norsteroid with anti-progesterone and anti glucocorticoid activity which competitively inhibits binding of the hormone to its receptor

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo matching mifepristone
Study: NCT01377506

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: lifestyle counseling
Description: 21 session group-based behavioral weight management program delivered in senior center over 12 months by lay health educators

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Training
Description: 21 session group-based cognitive training program delivered in senior center over 12 months by lay health educators
Study: NCT01132755

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Diagnostic peritoneal lavage
Description: The Veress needle will be inserted in the abdominal wall, at a site to be left up to the individual surgeon. Caudal traction will be applied to the abdominal wall to provide a firm abdominal wall to insert the needle through, minimizing the peritoneum from tenting down closer to visceral structures. Intraperitoneal placement of the catheter will be confirmed by injection of saline into the needle with no resistance and with the saline in the hub of the needle falling into the peritoneal cavity spontaneously. A guide wire will be placed through the Veress and utilizing the Seldinger technique, a 9Fr peritoneal catheter will be placed.
Study: NCT00444249

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: White Alcon IOL
Description: Implantation of white Alcon IOL

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Yellow Alcon IOL
Description: Implantation of yellow Alcon IOL

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: White Hoya IOL
Description: Implantation of white Hoya IOL

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Yellow Hoya IOL
Description: Implantation of yellow Hoya IOL
Study: NCT02769520

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg will be administered by IV infusion every 3 weeks up to 12 months or until disease progression
Study: NCT00762177

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fluoride
Description: Brush twice a day for 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluoride, Triclosan
Description: Brush twice daily for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stannous Fluoride
Description: Brush twice daily for 14 days
Study: NCT01486394

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Focused Sonography of the heart, lungs and deep veins
Description: The patient is randomised to either a control group where usual treatment and diagnostic work-up is performed or to an intervention group where usual treatment and diagnostic workup are supplemented by a sonographic examination of the heart, lungs and deep veins are performed within one hour after the primary evaluation. The primary evaluation is defined as the first evaluation of the patient by a physician in the Acute Medical Admission Department.
Study: NCT03826004

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clemastine
Description: Clemastine fumarate 2mg/2ml intramuscular injection is administrated into the gluteus maximus muscle

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline Solution
Description: Saline solution 2ml intramuscular injection is administrated into the gluteus maximus muscle
Study: NCT00731003

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxitriptan
Description: 100 mg 5-Hydroxytryptophan will be administered orally.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acute tryptophan depletion
Description: Acute tryptophan depletion employs the oral ingestion of an amino acid mixture devoid of tryptophan, the precursor of serotonin, which results in lowered serotonin levels.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Amino acid drink with tryptophan
Description: Amino acid drink with tryptophan, placebo for the ATD procedure

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsule
Description: Placebo for 5-HTP
Study: NCT01457430

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icatibant
Description: 30 mg subcutaneous dose of Icatibant
Study: NCT00401115

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MS-R001 (rapamycin)
Description: Subconjunctival injection in various dosages

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MS-R001 (rapamycin)
Description: Intraocular injection in various dosages
Study: NCT03899090

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Float pool
Description: Subject floats supine in a pool of water saturated with Epsom salt in an environment which minimizes stimulation of the nervous system, including reduced light, sound, and pressure on the spinal cord.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Float pool
Description: Subject floats supine in a pool of water saturated with Epsom salt in an environment which minimizes stimulation of the nervous system, including reduced light, sound, and pressure on the spinal cord.